secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2023-08-30T23:59:59+00:00
Accession:  0001558370-23-015362
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Q4 adj diluted EPS up 5% to $0.38; full-year net income down 34%
-----------------------------------------------------------------------

- Q4 net sales $255.0M (flat YoY); net income $11.5M (+54%); adj diluted EPS $0.38 (+5%).
- FY2023 net sales $977.9M (+4%); net income $32.6M (-34%); adj diluted EPS $1.21 (-8%).
- FY2024 guidance: net sales $1.0-1.05B; adj EBITDA $115-121M; adj diluted EPS $1.12-1.27.
- Animal Health FY sales +9% to $659.9M; Mineral Nutrition -6%; gross leverage 4.2x.
- Free cash flow negative $24M; liquidity $248M; pension settlement to incur ~$10.4M expense in Q1 FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837023015362/0001558370-23-015362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837023015362/pahc-20230830x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer